Patents by Inventor Michael Gazda

Michael Gazda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF REDUCING NEUROPATHY AND NEUROPATHIC SYMPTOMS AND TREATING CANCER
    Publication number: 20240316146
    Abstract: Disclosed herein are methods for reducing neuropathy and neuropathic symptoms and/or promoting neurogenesis, neuritogenesis, neuroprotection and neuroregeneration using saposin C-phospholipid compositions. Also disclosed are methods for treating cancer by administering a saposin C-phospholipid nanovesicle formulation and one or more antineoplastic agents or immune checkpoint inhibitors, and kits for the treatment of cancer comprising, in separate containers, (a) a saposin C-phospholipid pharmaceutical composition, and (b) a pharmaceutical composition containing an antineoplastic agent or a pharmaceutical composition containing an immune checkpoint inhibitor.
    Type: Application
    Filed: January 7, 2022
    Publication date: September 26, 2024
    Applicant: Bexion Pharmaceuticals Inc
    Inventors: Ray Takigiku, Darren P. Wolfe, Anne Mary Noonan, Robert Wesolowski, Charles A. Cruze, III, Gilles Hugues Tapolsky, Richard Charles Curry, III, Michael Gazda
  • 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
    Patent number: 6486190
    Abstract: Benzimidazole compounds having the generic structure: are used to treat alpha-2 mediated disorders, including nasal congestion, glaucoma, asthma, migraine, and diarrhea.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: November 26, 2002
    Assignee: The Procter & Gamble Company
    Inventors: Thomas Lee Cupps, Sophie Eva Bogdan, Nick Nikolaides, Sheri Ann Gilbert, Michael Gazda, Roy Lee Dobson, Charles Andrew III Cruze